Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma
- PMID: 35119508
- DOI: 10.1007/s00251-021-01246-1
Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma
Abstract
Costimulatory molecules were considered to be promising and important targets in immunotherapy for various cancers. The present study was intended for generating a costimulatory molecule signature in kidney renal clear cell carcinoma (KIRC), to investigate prognostic implication, elucidate immune atlas, and predict immunotherapy response. All the KIRC samples from the TCGA were randomly divided into the training dataset and the testing dataset in the ratio of 7:3. The Cox and least absolute shrinkage and selection operator (LASSO) regression analysis were used to identify 7 key costimulatory molecules which were associated with prognosis and construct a costimulatory molecule prognostic index (CMsPI), which was validated by internal and external datasets and an independent cohort. Patients in the high-CMsPI group had high mortality. Mutation analysis showed the most common mutational genes and variant types. Immune analysis demonstrated CD8+ T cells were infiltrated at a high level in the high-CMsPI group. In combination of analysis of the immune relevant gene signature and the biomarkers of immunotherapy, we may infer there were more dysfunctional CD8+ T cells in the high-CMsPI group, and the patients of this group were less sensitive to immunotherapy. A nomogram was constructed, and the concordance index was 0.77 (95% CI: 0.74-0.79). Three key signaling pathways were identified to facilitate tumor progression. The CMsPI can be regarded as a promising biomarker for predicting individual prognosis and assessing immunotherapy response in KIRC patients.
Keywords: Costimulatory molecule; Immune profile; Immunotherapy response; Kidney renal clear cell carcinoma; Nomogram.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.J Clin Lab Anal. 2022 Jun;36(6):e24409. doi: 10.1002/jcla.24409. Epub 2022 Apr 20. J Clin Lab Anal. 2022. PMID: 35441741 Free PMC article.
-
Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.Front Immunol. 2022 Sep 23;13:933241. doi: 10.3389/fimmu.2022.933241. eCollection 2022. Front Immunol. 2022. PMID: 36211378 Free PMC article.
-
Identification and validation of a two-gene metabolic signature for survival prediction in patients with kidney renal clear cell carcinoma.Aging (Albany NY). 2021 Mar 3;13(6):8276-8289. doi: 10.18632/aging.202636. Epub 2021 Mar 3. Aging (Albany NY). 2021. PMID: 33686951 Free PMC article.
-
Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.Crit Rev Eukaryot Gene Expr. 2022;32(1):79-98. doi: 10.1615/CritRevEukaryotGeneExpr.2021039325. Crit Rev Eukaryot Gene Expr. 2022. PMID: 35377983
-
Identification of small molecule drugs and development of a novel autophagy-related prognostic signature for kidney renal clear cell carcinoma.Cancer Med. 2020 Oct;9(19):7034-7051. doi: 10.1002/cam4.3367. Epub 2020 Aug 11. Cancer Med. 2020. PMID: 32780567 Free PMC article.
Cited by
-
Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer.Sci Rep. 2023 Jan 16;13(1):789. doi: 10.1038/s41598-023-27826-7. Sci Rep. 2023. PMID: 36646765 Free PMC article.
-
A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma.Front Immunol. 2022 Jul 22;13:928742. doi: 10.3389/fimmu.2022.928742. eCollection 2022. Front Immunol. 2022. PMID: 35935979 Free PMC article.
References
-
- Amatore F, Gorvel L, Olive D (2020) Role of inducible co-stimulator (ICOS) in cancer immunotherapy. Expert Opin Biol Ther 20(2):141–150. https://doi.org/10.1080/14712598.2020.1693540 - DOI - PubMed
-
- Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18(1):220. https://doi.org/10.1186/s13059-017-1349-1 - DOI - PubMed - PMC
-
- Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, ... de Reyniès A (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218. https://doi.org/10.1186/s13059-016-1070-5
-
- Burugu S, Dancsok AR, Nielsen TO (2018) Emerging targets in cancer immunotherapy. Semin Cancer Biol 52(Pt 2):39–52. https://doi.org/10.1016/j.semcancer.2017.10.001 - DOI - PubMed
-
- Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, ... Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248–262. https://doi.org/10.1016/j.celrep.2016.12.019
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
